Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-4

  Hodge, James W ^a   Kwilas, Anna ^a   Ardiani, Andressa ^a   Gameiro, Sofia R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigen processing machinery; Calreticulin; CTL mediated lysis; Immunogenic modulation; Immunotherapy; Therapeutic cancer vaccine

Indexed keywords

ABC TRANSPORTER A1; ATP BINDING CASSETTE TRANSPORTER 1B; CALRETICULIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; ENZALUTAMIDE; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NAVELBINE; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTIGEN FUNCTION; ANTIGEN PROCESSING MACHINERY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; IMMUNOGENIC CELL DEATH; IMMUNOGENIC MODULATION; IMMUNOGENICITY; NONHUMAN; PROTO ONCOGENE; RADIOFREQUENCY ABLATION;

EID: 84896694475     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26937     Document Type: Article

References (10)

1. Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012; 39:323-39; PMID:22595055; http://dx.doi.org/10.1053/j. seminoncol.2012.02.006
2. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008
3. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011; 60:1227-42; PMID:21544650; http://dx.doi. org/10.1007/s00262-011-1020-8
4. Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One 2013; 8:e70417; PMID:23894654; http://dx.doi. org/10.1371/journal.pone.0070417
5. Ardiani A, Farsaci B, Rogers CJ, Protter AA, Guo Z, King TH, Apelian D, Hodge JW. Combination therapy with a second-generation androgen receptor antagonist and a aetastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 2013; (Forthcoming); PMID:24048332; http:// dx.doi.org/10.1158/1078-0432.CCR-13-1026
6. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013; 133:624-36; PMID:23364915; http://dx.doi.org/10.1002/ ijc.28070
7. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-71; PMID:16636135; http://dx.doi.org/10.1084/ jem.20052494
8. Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest 2006; 35:485-503; PMID:16916763; http://dx.doi. org/10.1080/08820130600808246
9. C.R. Heery NKI, M. Mohebtash, R.A. Madan, P.M. Arlen, M. Bilusic, J.W. Kim, N.K. Singh, S. Hodge, S. McMahon, S.M. Steinberg, J.W. Hodge, J. Schlom, J. Gulley. A phase 2 randomized trial of docetaxel alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM. Cancer research 2012; 72(24 Suppl):Abstract nr P5-16-06
10. Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, et al. Interim analysis of a phase II randomized clinical trial of samarium-153 (Sm-153) with or without PSATRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. In: American Society of Clinical Oncology: 2012; Chicago, Illinois: ASCO; 2012: 2526.